about
Factors influencing the participation of gastroenterologists and hepatologists in clinical research.Eltrombopag: Is this "24 karat gold platelet" treatment for thrombocytopenia in cirrhosis associated with hepatitis C?Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression.Insulin resistance and steatosis in hepatitis C virus infection.Steatosis and chronic hepatitis C virus infection: mechanisms and significance.Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C.Chronic hepatitis B infection in an Australian antenatal population: seroprevalence and opportunities for better outcomes.Historical epidemiology of hepatitis C virus (HCV) in selected countries.Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury.Adherence to Hepatitis B Antiviral Therapy: A Qualitative Study.Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.A novel assay for detection of hepatitis C virus-specific effector CD4(+) T cells via co-expression of CD25 and CD134.Factors associated with medication adherence in patients living with cirrhosis.Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.Factors associated with HBV virological breakthrough.Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.Strategies to manage hepatitis C virus (HCV) disease burden.Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.Cytokines and liver injury in chronic HCV genotype 4 infection.Palliation of hilar biliary obstruction from colorectal metastases by endoscopic stent insertion.The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection.A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection.Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.Factors associated with non-adherence to HBV antiviral therapy.Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C.Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.Is re-treatment with peginterferon alpha-2a and ribavirin effective in patients with relapsed chronic hepatitis C?Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths.The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection.Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy.Tinkering and tailoring with HCV therapy: can we get away with less?Treatment of acute hepatitis C infection: more pieces of the puzzle?
P50
Q33374640-08FFE5A1-7302-4B24-80C6-B684FD48988AQ33379071-B5357C6A-059B-4773-8B4C-4F3726F8B448Q35016133-10555ADD-C118-4A9B-86E3-BFF0C80617B4Q35044131-95400E97-AD1B-44B9-91E3-B4650F565E7CQ36160709-6BB9A735-52F8-4D7D-84E2-76084FDC4B5CQ36197552-6A9821A8-C2E4-4B80-8CBE-44A2540D39F4Q37091088-AF25B1A6-4430-4EFB-9995-6050B30CB82AQ37564617-C6A36050-9F3C-43A6-82F4-D9CE09BE7764Q38203033-6950E55C-A9E4-4E4A-B026-2EA842FB3BC9Q38233245-485279E4-A850-46CC-84AA-E2019B59C4E5Q38490006-3BCF516B-1110-4DF2-9D5C-F6F6B3B493ABQ38750970-F4492F0E-39A8-44DC-98B9-3AA340137216Q38830892-8B2DA70A-2CD8-4F28-89C3-7F10932BAC51Q39213684-9A703775-3BC8-462D-9004-2F02295E681DQ39454467-CAB3AC5C-291B-4FC8-85B2-2066792BADFCQ40106356-36145158-5008-4E57-91AA-D09514FFAAAAQ40563923-8F47232B-3E9B-419E-A9A7-B0C5316167E3Q40580597-286D63DD-3127-486D-AB2D-7B624B9FA67BQ41359934-AA04D636-4301-4479-82D9-BEC722645D59Q41686499-9428F71C-FB9D-45D5-B3D5-6C622DBC4339Q42226125-06966016-4545-4332-B19A-E445E47E610BQ42241367-C7917136-581A-418E-B962-4B13E8028898Q42977363-615D15D1-47BB-4AA5-9A6F-7615E3EB76D0Q42986605-B0C73017-5063-4459-963E-4FF90967FCC6Q45142888-220660CB-698D-4EE4-9183-7E5F63988C04Q45362053-7B4BE2E6-4118-4BF9-A28B-FE4D0B2693F8Q45392520-F242974F-B7DA-45F5-9922-A426D142D3A6Q47448294-81639481-5936-4ECA-9B47-455AF391EB3BQ47550541-71016193-A4A3-4C63-876F-C215E3C4F04BQ47744805-CB45833C-D1AC-4B80-AB7C-D5658E51A9CFQ48286570-774215C6-BE43-4D52-BD10-45FCAC5F8205Q50099174-0CE677AD-C637-4220-A7A3-EF4806CA758DQ50574459-E09F4EAF-A867-47C3-BFB8-15E74F7B06BBQ50577613-A9BB3FFD-E9E9-46C4-8689-378AED89CD97Q51020577-48618CBC-1F58-4D14-B287-9B283BD0B4FFQ51767008-6B0A10E0-10C8-4EC7-ADA0-F35559E69C8BQ54244526-077EAC07-9CE2-4E6C-85CA-DD41DE1BD94AQ81044477-8F325BB3-63A5-4847-82CC-4B4386602850Q81400029-99AFCA58-4C2E-4B68-847A-9DE722D9DCFA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amany Zekry
@ast
Amany Zekry
@en
Amany Zekry
@es
Amany Zekry
@nl
type
label
Amany Zekry
@ast
Amany Zekry
@en
Amany Zekry
@es
Amany Zekry
@nl
prefLabel
Amany Zekry
@ast
Amany Zekry
@en
Amany Zekry
@es
Amany Zekry
@nl
P106
P1153
6701704541
P31
P496
0000-0002-5675-1810